References

russjcardiol

Российский кардиологический журнал

Russian Journal of Cardiology

1560-40712618-7620

«SILICEA-POLIGRAF» LLC

10.15829/1560-4071-2020-4076

russjcardiol-4076

Research Article

КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ

CLINICAL GUIDELINES

Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020

2020 Clinical practice guidelines for Stable coronary artery disease

Российское кардиологическое общество (РКО)

Russian Society of Cardiology (RSC)

V_kash@mail.ru

2020

30112020

251140764076

2020

Российское кардиологическое общество (РКО) ..

Russian Society of Cardiology (RSC) ..

This work is licensed under a Creative Commons Attribution 4.0 License.

https://russjcardiol.elpub.ru/jour/article/view/4076

Одобрено Научно-практическим Советом Минздрава Российской Федерации.

Approved by the Research and Practical Council of the Ministry of Health of the Russian Federation.

ишемическая болезнь сердцастабильная стенокардияоптимальная медикаментозная терапияреваскуляризация миокардапрогнозкачество жизнирекомендации

coronary artery diseasestable anginaoptimal medical therapymyocardial revascularizationprognosisquality of lifeguidelines

References1

Sackett DL, Rosenberg WM, Gray JA et al. Evidence based medicine: what it is and what it isn't. BMJ 1996;312(7023):71-2. doi:10.1136/bmj.312.7023.71.

Федеральный закон от 21.11.2011 № 323-ФЗ (ред. от 03.04.2017) “Об основах охраны здоровья граждан в Российской Федерации”.

Federal law No. 323-FZ of 21.11.2011 (ed. from 03.04.2017) “on the basics of public health protection in the Russian Federation”. (In Russ.)

Эпидемиологический словарь: под ред. Джона М. Ласта для Международной эпидемиологической ассоциации. 4-е изд. М., 2009. 316 с.

Epidemiological dictionary: ed. John M. last for the International epidemiological Association. 4th ed., Moscow, 2009, 316 p. (In Russ.)

ГОСТР 52379-2005. Надлежащая клиническая практика. М.: Стандартинформ, 2005. 39 с.

GOSTR 52379-2005. Good clinical practice, Moscow: Standardinform, 2005, 39 p. (In Russ.)

Федеральный закон от 12.04.2010 № 61-ФЗ (ред. от 03.07.2016) “Об обращении лекарственных средств”.

Federal Law No. 61-FZ of 12.04.2010 (ed. from 03.07.2016) “On the Circulation of Medicines”. (In Russ.)

Малая медицинская энциклопедия. М.: Медицинская энциклопедия, 1991-1996гг. http://dic.academic.ru/dic.nsf/enc_medicine/28878/CuHgpoM.

Small Medical Encyclopedia. M.: Medical Encyclopedia, 1991-1996. (In Russ.)

Андреева Н.С., Реброва О.Ю., Зорин Н. А. и др. Системы оценки достоверности научных доказательств и убедительности рекомендаций: сравнительная характеристика и перспективы унификации. Медицинские технологии. Оценка и выбор. 2012;4:10-24.

Andreeva NS, Rebrova OYu, Zorin NA, et al. Systems for assessing the reliability of scientific evidence and the persuasiveness of recommendations: comparative characteristics and prospects for unification. Medical technology. Evaluation and selection. 2012;4:10-24. (In Russ.)

Руководство по кардиологии: под ред. акад. Е. И. Чазова. В 4 т. М.: Издательский дом “Практика”, 2014.

Guidelines for Cardiology: edited by Acad. EI. Chazova. In 4 volumes. Moscow: Praktika Publishing House, 2014. (In Russ.)

Карпов Ю. А., Сорокин Е. В. Стабильная ишемическая болезнь сердца: стратегия и тактика лечения. 2-е изд., перераб. и доп. М.: Медицинское информационное агентство, 2012. 271 с. ISBN 978-5-9986-0080-7.

Karpov YuA, Sorokin EV. Stable ischemic heart disease: strategy and tactics of treatment. 2nd ed., Revised and enlarged. Moscow: Medical Information Agency, 2012. 271 p. (In Russ.)

Карпов Ю. А., Кухарчук В. В., Лякишев А. и др. Диагностика и лечение хронической ишемической болезни сердца. Практические рекомендации. Кардиологический вестник. 2015;3:3-33.

Karpov YuA, Kukharchuk VV, Lyakishev A, et al. Diagnosis and treatment of chronic ischemic heart disease. Practical advice. Cardiological Bulletin. 2015;3:3-33. (In Russ.)

Кардиология: национальное руководство: под ред. Е. В. Шляхто. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2015. 800 с. ISBN 978-5-9704-4810-6.

Cardiology: national guidelines: ed. EV. Shlyakhto. 2nd ed., Revised and enlarged. M.: GEOTAR-Media, 2015. 800 p. (In Russ.)

Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines on the diagnosis and management of chronic coronary syndromes: the task force for diagnosis and management of chronic coronary syndromes of the European society of cardiology (ESC) Eur Heart J. 2020;41:407-477. doi: 10.1093/eurheartj/ehz425.

Campeau L. Letter: Grading of angina pectoris. Circulation. 1976;54:522-3.

International classification of diseases ICD-10. (In Russ.) Международная классификация болезней МКБ-10. http://www.mkb10.ru.

Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD. Fourth universal definition of myocardial infarction. European Heart Journal. 2019;40(3):237-69. doi:10.1093/eurheartj/ehy462.

Диагностика и лечение стабильной ишемической болезни сердца. Клинические рекомендации. М.; 2013. 69 с.

Diagnosis and treatment of stable coronary heart disease. Clinical guidelines. M.; 2013.69 p. (In Russ.)

Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronaryartery disease. N Engl J Med. 1979;300:1350-8. doi:10.1056/NEJM197906143002402.

Genders TS, Steyerberg EW, Alkadhi H, et al. A clinical prediction rule for the diagnosis of coronary artery disease: validation, updating, and extension. Eur Heart. J 2011;32:1316-30. doi:10.1093/eurheartj/ehr014.

Foldyna B, Udelson JE, Karady J, et al. Pretest probability for patients with suspected obstructive coronary artery disease: re-evaluating Diamond-Forrester for the contemporary era and clinical implications: insights from the PROMISE trial. Eur Heart J Cardiovasc Imaging. 2018;20:574-81. doi:10.1093/ehjci/jey182.

Adamson PD, Newby DE, Hill CL, et al. Comparison of international guidelines for assessment of suspected stable angina: insights from the PROMISE and SCOT-HEART. JACC Cardiovasc Imaging. 2018;11:1301-10. doi:10.1016/j.jcmg.2018.06.021.

Montalescot G, SechtemU, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable Coronary artery disease of European Society of Cardiology. Eur Heart J. 2013;34:2949-3003. doi:10.1093/eurheartj/eht296.

Арутюнов Г.П., Бойцов С. А., Воевода М. И. и др. Коррекция гипертриглицеридемии с целью снижения остаточного риска при заболеваниях, вызванных атеросклерозом. Заключение Совета экспертов. Российский кардиологический журнал. 2019;(9):44-51. doi:10.15829/1560-4071-2019-9-44-51.

Arutyunov GP, Boytsov SA, Voevoda MI, et al. Correction of hypertriglyceridemia in order to reduce the residual risk in diseases caused by atherosclerosis. Conclusion of the Council of Experts. Russian Journal of Cardiology. 2019;(9):44-51. (In Russ.)

Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European Heart Journal. 2016;37(29):2315-381. doi:10.1093/eurheart/ehw106.

Кухарчук В. В., Коновалов Г. А., Сусеков А. В. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VI пересмотр. М., 2017. 44 с.

Kukharchuk VV, Konovalov GA, Susekov AV, et al. Diagnosis and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations, VI revision. M., 2017. 44 p. (In Russ.)

Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999-3058. doi:10.1093/eurheartj/ehw272.

Cohn PF, Fox KM, Daly C. Silent myocardial ischemia. Circulation. 2003;108:1263-77. doi:10.1161/01.CIR.0000088001.59265.EE.

Androulakis A, Aznaouridis KA, Aggeli CJ, et al. Transient ST-segment depression during paroxysms of atrial fibrillation in otherwise normal individuals: relation with underlying coronary artery disease. J Am Coll Cardiol. 2007;50:1909-11. doi:10.1016/j.jacc.2007.08.005.

Steeds RP, Garbi M, Cardim N, et al. EACVI appropriateness criteria for the use of transthoracic echocardiography in adults: a report of literature and current practice review. Eur Heart J Cardiovasc Imaging. 2017;18:1191-204. doi:10.1093/ehjci/jew333.

Daly CA, De Stavola B, Sendon JL, et al. Predicting prognosis in stable angina — results from the Euro heart survey of stable angina: prospective observational study. BMJ. 2006;332:262-7. doi:10.1136/bmj.38695.605440.AE.

Smedsrud MK, Gravning J, Omland T, et al. Sensitive cardiac troponins and N-terminal pro-B-type natriuretic peptide in stable coronary artery disease: correlation with left ventricular function as assessed by myocardial strain. Int J Cardiovasc Imaging. 2015;31:967-73. doi:10.1007/s10554-015-0646-6.

Senior R, Becher H, Monaghan M, et al. Clinical practice of contrast echocardiography: recommendation by the European Association of Cardiovascular Imaging (EACVI) 2017. Eur Heart J Cardiovasc Imaging. 2017;18:1205-1205af. doi:10.1093/ehjci/jex182.

Thomson HL, Basmadjian AJ, Rainbird AJ, et al. Contrast echocardiography improves the accuracy and reproducibility of left ventricular remodeling measurements: a prospective, randomly assigned, blinded study. J Am Coll Cardiol. 2001;38:867-75. doi:10.1016/s0735-1097(01)01416-4.

Greenwood JP, Ripley DP, Berry C, et al. Effect of care guided by cardiovascular magnetic resonance, myocardial perfusion scintigraphy, or NICE guidelines on subsequent unnecessary angiography rates: the CE-MARC 2 randomized clinical trial. JAMA. 2016;316:1051-60. doi:10.1001/jama.2016.12680.

Boogers MJ, Broersen A, Van Velzen JE, et al. Automated quantification of coronary plaque with computed tomography: comparison with intravascular ultrasound using a dedicated registration algorithm for fusion-based quantification. Eur. Heart J. 2012;33(8):1007-16. doi:10.1093/eurheartj/ehr465.

Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim intima-media thickness consensus. Cerebrovasc Dis. 2004;18:346-9. doi:10.1159/000081812.

Vlachopoulos C, Xaplanteris P, Aboyans V, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis. 2015;241:507-32. doi:10.1016/j.atherosclerosis.2015.05.007.

Forslund L, Hjemdahl P, Held C, et al. Ischaemia during exercise and ambulatory monitoring in patients with stable angina pectoris and healthy controls. Gender differences and relationships to catecholamines. Eur Heart J. 1998;19:578-87. doi:10.1053/euhj.1997.0819.

Davies RF, Goldberg AD, Forman S, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation. 1997;95:2037-43. doi:10.1161/01.CIR.95.8.2037.

Stone PH, Chaitman BR, Forman S, et al. Prognostic significance of myocardial ischemia detected by ambulatory electrocardiography, exercise treadmill testing, and electrocardiogram at rest to predict cardiac events by one year (the Asymptomatic Cardiac Ischemia Pilot (ACIP) study). Am J Cardiol. 1997;80:1395-401. doi:10.1016/S0002-9149(97)00706-6.

Versteylen MO, Joosen IA, Shaw LJ, et al. Comparison of Framingham, PROCAM, SCORE, and Diamond Forrester to predict coronary atherosclerosis and cardiovascular events. J Nucl Cardiol. 2011;18:904-11. doi:10.1007/s12350-011-9425-5.

Fordyce CB, Douglas PS, Roberts RS, et al. Identification of patients with stable chest pain deriving minimal value from noninvasive testing: the PROMISE minimal-risk tool, a secondary analysis of a randomized clinical trial. JAMA Cardiol. 2017;2:400-8. doi:10.1001/jamacardio.2016.5501.

Jensen JM, Voss M, Hansen VB, et al. Risk stratification of patients suspected of coronary artery disease: comparison of five different models. Atherosclerosis. 2012;220:557-62. doi:10.1016/j.atherosclerosis.2011.11.027.

Budoff MJ, Mayrhofer T, Ferencik M, et al. Prognostic value of coronary artery calcium in the PROMISE study (Prospective Multicenter Imaging Study for Evaluation of Chest Pain). Circulation. 2017;136:1993-2005. doi:10.1161/CIRCULATIONAHA.117.030578.

Reeh J, Therming CB, Heitmann M, et al. Prediction of obstructive coronary artery disease and prognosis in patients with suspected stable angina. Eur Heart J. 2018;40:1426-35. doi:10.1093/eurheartj/ehy806.

Siontis GC, Mavridis D, Greenwood JP, et al. Outcomes of non-invasive diagnostic modalities for the detection of coronary artery disease: network meta-analysis of diagnostic randomised controlled trials. BMJ. 2018;360:k504. doi:10.1136/bmj.k504.

Hoffmann U, Ferencik M, Udelson JE, et al. Prognostic value of noninvasive cardiovascular testing in patients with stable chest pain: insights from the PROMISE trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain). Circulation. 2017;135:2320-32. doi:10.1161/CIRCULATIONAHA.116.024360.

de Azevedo CF, Hadlich MS, Bezerra SG, et al. Prognostic value of CT angiography in patients with inconclusive functional stress tests. JACC Cardiovasc Imaging. 2011;4:740-51. doi:10.1016/j.jcmg.2011.02.017.

Knuuti J, Ballo H, Juarez-Orozco LE, et al. The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability. Eur Heart J. 2018;39:3322-30. doi:10.1093/eurheartj/ehy267.

Zacharias K, Ahmed A, Shah BN, et al. Relative clinical and economic impact of exercise echocardiography vs. exercise electrocardiography, as first line investigation in patients without known coronary artery disease and new stable angina: a randomized prospective study. Eur Heart J Cardiovasc Imaging. 2017;18:195-202. doi:10.1093/ehjci/jew049.

Williams MC, Hunter A, Shah ASV, et al. Use of coronary computed tomographic angiography to guide management of patients with coronary disease. J Am Coll Cardiol. 2016;67:1759-68. doi:10.1016/j.jacc.2016.02.026.

Knuuti J, Bengel F, Bax JJ, et al. Risks and benefits of cardiac imaging: an analysis of risks related to imaging for coronary artery disease. Eur Heart J. 2014;35:633-8. doi:10.1093/eurheartj/eht512.

Jorgensen ME, Andersson C, Norgaard BL, et al. Functional testing or coronary computed tomography angiography in patients with stable coronary artery disease. J AmColl Cardiol. 2017;69:1761-70. doi:10.1016/j.jacc.2017.01.046.

Roifman I, Wijeysundera HC, Austin PC, et al. Comparison of anatomic and clinical outcomes in patients undergoing alternative initial noninvasive testing strategies for the diagnosis of stable coronary artery disease. J Am Heart Assoc. 2017;6:e005462. doi:10.1161/JAHA.116.005462.

Navare SM, Mather JF, Shaw LJ, et al. Comparison of risk stratification with pharmacologic and exercise stress myocardial perfusion imaging: a meta-analysis. J Nucl Cardiol. 2004;11(5):551-61. doi:10.1016/j.nuclcard.2004.06.128.

Koshy AN, Ha FJ, Gow PJ, et al. Computed tomographic coronary angiography in risk stratification prior to non-cardiac surgery: a systematic review and meta-analysis. Heart. 2019;105(17):1335-42. doi:10.1136/heartjnl-2018-314649.

Johnson NP, Toth GG, Lai D, et al. Prognostic value of fractional flow reserve: linking physiologic severity to clinical outcomes. J Am Coll Cardiol. 2014;64:1641-54. doi:10.1016/j.jacc.2014.07.973.

Barbato E, Toth GG, Johnson NP, et al. A prospective natural history study of coronary atherosclerosis using fractional flow reserve. J Am Coll Cardiol. 2016;68:2247-55. doi:10.1016/j.jacc.2016.08.055.

Меркулов Е. В., Миронов В. М., Самко А. Н. Коронарная ангиография, вентрикулография, шунтография. В иллюстрациях и схемах. М.: Медиа-Медика, 2011. 100 с. ISBN: 978-5-905305-03-0.

Merkulov EV, Mironov VM, Samko AN. Coronary angiography, ventriculography, shuntography. In illustrations and diagrams. M.: Media-Medica, 2011. 100 p. (In Russ.)

Zimmermann FM, Omerovic E, Fournier S, et al. Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data. Eur Heart J. 2019;40(2):180-6. doi:10.1093/eurheartj/ehy812.

Emond M, Mock MB, Davis KB, et al. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation. 1994;90:2645-57. doi:10.1161/01.cir.90.6.2645.

DeBruyne B, Pijls NH, Kalesan B, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367:991-1001. doi:10.1056/NEJMoa1205361.

Chamuleau SA, Meuwissen M, Koch KT, et al. Usefulness of fractional flow reserve for risk stratification of patients with multivessel coronary artery disease and an intermediate stenosis. Am J Cardiol. 2002;89(4):377-80. doi:10.1016/s0002-9149(01)02255-x.

Миронов В.М., Меркулов Е. В., Терещенко А. С., и др. Измерение фракционного резерва кровотока для выбора тактики лечения пациентов с многососудистым и многоуровневым поражением коронарного русла. Атеросклероз и дислипидемии. 2014;2(15):17-22.

Mironov VM, Merkulov EV, Tereshchenko AS, et al. Measurement of fractional reserve blood flow for the choice of treatment tactics in patients with multivessel and multilevel coronary lesions. Atherosclerosis and dyslipidemia, 2014;2(15):17-22. (In Russ.)

Liou K, Negishi K, Ho S, et al. Detection of Obstructive Coronary Artery Disease Using Peak Systolic Global Longitudinal Strain Derived by Two-Dimensional Speckle-Tracking: A Systematic Review and Meta-Analysis. J Am Soc Echocardiogr. 2016;29(8):724-35.e4. doi:10.1016/j.echo.2016.03.002.

Sara JD, Widmer RJ, Matsuzawa Y, et al. Prevalence of coronary microvascular dysfunction among patients with chest pain and nonobstructive coronary artery disease. JACC Cardiovasc Interv. 2015;8:1445-53. doi:10.1016/j.jcin.2015.06.017.

Lee BK, Lim HS, Fearon WF, et al. Invasive evaluation of patients with angina in the absence of obstructive coronary artery disease. Circulation. 2015;131:1054-60. doi:10.1161/CIRCULATIONAHA.114.012636.

Ong P, Athanasiadis A, Borgulya G, et al. Clinical usefulness, angiographic characteristics, and safety evaluation of intracoronary acetylcholine provocation testing among 921 consecutive white patients with unobstructed coronary arteries. Circulation. 2014;129:1723-30. doi:10.1161/CIRCULATIONAHA.113.004096.

Schoenenberger AW, Adler E, Gujer S, et al. Prognostic value of an abnormal response to acetylcholine in patients with angina and non-obstructive coronary artery disease: longterm follow-up of the Heart Quest cohort. Int J Cardiol. 2016;221:539-45. doi:10.1016/j.ijcard.2016.07.035.

Aziz A, Hansen HS, Sechtem U, et al. Sex-related differences in vasomotor function in patients with angina and unobstructed coronary arteries. J Am Coll Cardiol. 2017;70:2349-58. doi:10.1016/j.jacc.2017.09.016.

Beltrame JF, Crea F, Kaski JC, et al. International standardization of diagnostic criteria for vasospastic angina. Eur Heart J. 2017;38:2565-68. doi:10.1093/eurheartj/ehv351.

JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary Spastic Angina) (JCS 2013). Circ J. 2014;78:2779-801. doi:10.1253/circj.cj-66-0098.

Ford TJ, Stanley B, Good R, et al. Stratified medical therapy using invasive coronary function testing in angina: the CorMicA trial. J Am Coll Cardiol. 2018;72:2841-55. doi:10.1016/j.jacc.2018.09.006.

Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739-91. doi:10.1093/eurheartj/ehx391.

Kass M, Allan R, Haddad H. Diagnosis of graft coronary artery disease. Curr Opin Cardiol. 2007;22:139-45. doi:10.1097/HCO.0b013e328021066b.

Baris N, Sipahi I, Kapadia SR, et al. Coronary angiography for follow-up of heart transplant recipients: insights from TIMI frame count and TIMI myocardial perfusion grade. J Heart Lung Transplant. 2007;26:593-7. doi:10.1016/j.healun.2007.03.016.

Zimmer RJ, Lee MS. Transplant coronary artery disease. JACC Cardiovasc Interv. 2010;3:367-77. doi:10.1016/j.jcin.2010.02.007.

D'Ascenzo F, Barbero U, Cerrato E, et al. Accuracy of intravascular ultrasound and optical coherence tomography in identifying functionally significant coronary stenosis according to vessel diameter: a meta-analysis of 2,581 patients and 2,807 lesions. Am Heart J. 2015;169(5):663-73. doi:10.1016/j.ahj.2015.01.013.

Waksman R, Legutko J, Singh J, et al. FIRST: Fractional Flow Reserve and Intravascular Ultrasound Relationship Study. J Am Coll Cardiol. 2013;61:917-23. doi:10.1016/j.jacc.2012.12.012.

Park SJ, Ahn JM, Kang SJ, et al. Intravascular ultrasound-derived minimal lumen area criteria for functionally significant left main coronary artery stenosis. JACC Cardiovasc Interv. 2014;7:868-74. doi:10.1016/j.jcin.2014.02.015.

Ben-Dor I, Torguson R, Deksissa T, et al. Intravascular ultrasound lumen area parameters for assessment of physiological ischemia by fractional flow reserve in intermediate coronary artery stenosis. Cardiovasc Revasc Med. 2012;13(3):177-82. doi:10.1016/j.carrev.2011.12.003.

Mark DB, Shaw L, Harrell FE Jr, et al. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N Engl J Med. 1991;325:849-53. doi:10.1056/NEJM199109193251204.

Maaniitty T, Stenstrom I, Bax JJ, et al. Prognostic value of coronary CT angiography with selective PET perfusion imaging in coronary artery disease. JACC Cardiovasc Imaging. 2017;10:1361-70. doi:10.1016/j.jcmg.2016.10.025.

SCOT-HEART investigators. CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open-label, parallel-group, multicentre trial. Lancet. 2015;385:2383-91. doi:10.1016/S0140-6736(15)60291-4.

Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. doi:10.1093/eurheartj/ehy339.

Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957-67.

Xie X, Atkins E, Lv J, Bennett A, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435-43. doi:10.1016/S0140-6736(15)00805-3.

Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, et al. Aspirin 3567 in the primary and secondary prevention of vascular disease: collaborative meta-analysis of 3568 individual participant data from randomized trials. Lancet. 2009;373:1849-60. doi:10.1016/S0140-6736(09)60503-1.

CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348:1329-39. doi:10.1016/s0140-6736(96)09457-3.

Mauri L, Kereiakes DJ, Yeh RW, et al., DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155-66. doi:10.1056/NEJMoa1409312.

Mega JL, Braunwald E, Wiviott SD, et al; ATLAS ACS 2TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9-19. doi:10.1056/NEJMoa1112277.

Eikelboom JW, Connolly SJ, Bosch J, et al; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319-30. doi:10.1056/NEJMoa1709118.

Bonaca MP, Bhatt DL, Cohen M, et al; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791-800. doi:10.1056/NEJMoa1500857.

Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. Circulation. 1998;98(16):1597-603. doi:10.1161/01.cir.98.16.1597.

Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation. 1998; 98(20):2126-32. doi:10.1161/01.cir.98.20.2126.

Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213-60. doi:10.1093/eurheartj/ehx419.

Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov. 2010;9(2):154-69. doi:10.1038/nrd2957.

Lopes RD, Heizer G, Aronson R, et al; AUGUSTUS Investigators. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380:1509-24. doi:10.1056/NEJMoa1817083.

Cannon CP, Bhatt DL, Oldgren J, et al; RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377:1513-24. doi:10.1056/NEJMoa1708454.

Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423-34. doi:10.1056/NEJMoa1611594.

100

Giugliano RP, Ruff CT, Braunwald E, et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-104. doi:10.1056/NEJMoa1310907.

101

Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-962. doi:10.1093/eurheartj/ehw210.

102

Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347:969-74. doi:10.1056/NEJMoa020496.

103

Lopes RD, Leonardi S, Wojdyla DM, et al. Stent Thrombosis in Patients with Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. Circulation. 2020;141(9):781-3. doi:10.1161/CIRCULATIONAHA.119.044584.

104

Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without Omeprazole in Coronary Artery Disease. N Engl J Med. 2010;363:1909-17. doi:10.1056/NEJMoa1007964.

105

Kwok C, Shing, Jeevanantham V, et al. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: Meta-analysis. Int J Cardiol. 2012;167:965-74. doi:10.1016/j.ijcard.2012.03.085.

106

Huang B, Huang Y, Li Y, et al. Adverse Cardiovascular Effects of Concomitant Use of Proton Pump Inhibitors and Clopidogrel in Patients with Coronary Artery Disease: A Systematic Review and Meta-Analysis. Archives of Medical Research. 2012;43:212-24. doi:10.1016/j.arcmed.2012.04.004.

107

Melloni C, Washam JB, Jones WS, et al. Conflicting Results Between Randomized Trials and Observational Studies on the Impact of Proton Pump Inhibitors on Cardiovascular Events When Coadministered With Dual Antiplatelet Therapy. Systematic Review. Circ Cardiovasc Qual Outcomes. 2015;8:47-55. doi:10.1161/CIRCOUTCOMES.114.001177.

108

Sehested TSG, Carlson N, Hansen PW, et al. Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction. Eur Heart J. 2019;40:1963-70. doi:10.1093/eurheartj/ehz104.

109

Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455.

110

Murphy SA, Pedersen TR, Gaciong ZA, et al. Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial. JAMA Cardiol. 2019;4(7):613-9. doi:10.1001/jamacardio.2019.0886.

111

Szarek M, White HD, Schwartz GG, et al. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019;73:387-96. doi:10.1016/j.jacc.2018.10.039.

112

Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-17. doi:10.1056/NEJM199909023411001.

113

Rossignol P, Girerd N, Bakris G, et al. Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. Eur J Heart Fail. 2017;19:792-9. doi:10.1002/ejhf.688.

114

Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-200. doi:10.1093/eurheartj/ehw128.

115

Pauly DF, Johnson BD, Anderson RD et al. In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: a double-blind randomized study from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE). Am Heart J. 2011;162:678-84. doi:10.1016/j.ahj.2011.07.011.

116

Ong P, Athanasiadis A, Sechtem U. Pharmacotherapy for coronary microvascular dysfunction. Eur Heart J Cardiovasc Pharmacother. 2015;1:65-71. doi:10.1093/ehjcvp/pvu020.

117

Crea F, Lanza G. Treatment of microvascular angina: the need for precision medicine. European Heart Journal. 2016;37:1514-6. doi:10.1093/eurheartj/ehw021.

118

Buxton A, Goldberg S, Hirshfeld JW, et al. Refractory ergonovine-induced coronary vasospasm: importance of intracoronary nitroglycerin. Am J Cardiol. 1980;46:329-34. doi:10.1016/0002-9149(80)90080-6.

119

Сергиенко В.Б., Самойленко Е., Саютина Е.В. и др. Роль дисфункции эндотелия в развитии ишемии миокарда у больных ИБС с неизмененными и малоизмененными коронарными артериями. Кардиология. 1999;1:25-30.

Sergienko VB, Samoilenko E, Sayutina EV, et al. The role of endothelial dysfunction in the development of myocardial ischemia in patients with coronary artery disease with unchanged and slightly altered coronary arteries. Cardiology. 1999;1:25-30. (In Russ.)

120

Tsuburaya R, Takahashi J, Nakamura A et al. Beneficial effects of long acting nifedipine on coronary vasomotion abnormalities after drug-eluting stent implantation: the NOVEL study. Eur Heart J. 2016;37:2713-21. doi:10.1093/eurheartj/ehw256.

121

Boden WE, O'Rourke RA, Teo KK et al.; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-16. doi:10.1056/NEJMoa070829

122

BARI Study Group 2D, Frye RL, August P et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503-15. doi:10.1056/NEJMoa0805796.

123

Hueb W, Lopes N, Gersh BJ, et al. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): A randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation. 2010;122:949-57. doi:10.1161/CIRCULATIONAHA.109.911669.

124

Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: Overview of 10-year results from randomized trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet. 1994;344:563-70. doi:10.1016/s0140-6736(94)91963-1.

125

Bittl JA, He Y, Jacobs AK, et al. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Bayesian methods affirm the use of percutaneous coronary intervention to improve survival in patients with unprotected left main coronary artery disease. Circulation. 2013;127:2177-85. doi:10.1161/CIRCULATIONAHA.112.000646.

126

Dzavik V, Ghali WA, Norris C, et al., Alberta for Provincial Project in Outcome Assessment Coronary Heart Disease Investigators. Long-term survival in 11,661 patients with multivessel coronary artery disease in the era of stenting: A report from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. Am Heart J. 2001;142:119-26. doi:10.1067/mhj.2001.116072.

127

Lee PH, Ahn JM, Chang M, et al. Left main coronary artery disease: Secular trends in patient characteristics, treatments, and outcomes. J Am Coll Cardiol. 2016;68:1233-46. doi:10.1016/j.jacc.2016.05.089.

128

Smith PK, Califf RM, Tuttle RH, et al. Selection of surgical or percutaneous coronary intervention provides differential longevity benefit. Ann Thorac Surg. 2006;82:1420-8; discussion 1428-9. doi:10.1016/j.athoracsur.2006.04.044.

129

Hannan EL, Wu C, Walford G, et al. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N Engl J Med. 2008;358:331-41. doi:10.1056/NEJMoa071804.

130

Hannan EL, Samadashvili Z, Cozzens K, et al. Comparative outcomes for patients who do and do not undergo percutaneous coronary intervention for stable coronary artery disease in New York. Circulation 2012;125:1870-9. doi:10.1161/CIRCULATIONAHA.111.071811.

131

Caracciolo EA, Davis KB, Sopko G, et al. Comparison of surgical and medical group survival in patients with left main equivalent coronary artery disease. Long-term CASS experience. Circulation. 1995;91:2335-44. doi:10.1161/01.cir.91.9.2335.

132

Chaitman BR, Hardison RM, Adler D, et al; Bypass Angioplasty Revascularization Investigation 2 Diabetes Study G. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: Impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation. 2009;120:2529-40. doi:10.1161/CIRCULATIONAHA.109.913111.

133

Passamani E, Davis KB, Gillespie MJ, Killip T. A randomized trial of coronary artery bypass surgery. Survival of patients with a low ejection fraction. N Engl J Med. 1985;312:1665-71. doi:10.1056/NEJM198506273122603.

134

Velazquez EJ, Lee KL, Deja MA, et al.; STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364:1607-16. doi:10.1056/NEJMoa1100356.

135

Jones RH, Kesler K, Phillips HR III, et al. Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery disease. J Thorac Cardiovasc Surg. 1996;111:1013-25. doi:10.1016/s0022-5223(96)70378-1.

136

Baker DW, Jones R, Hodges J, et al. Management of heart failure. III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction. JAMA. 1994;272:1528-34. doi:10.1001/jama.272.19.1528.

137

Velazquez EJ, Lee KL, Jones RH, et al; STICHES Investigators. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med. 2016;374:1511-20. doi:10.1056/NEJMoa1602001.

138

Panza JA, Velazquez EJ, She L, et al. Extent of coronary and myocardial disease and benefit from surgical revascularization in ischemic LV dysfunction [Corrected]. J Am Coll Cardiol. 2014;64:553-61. doi:10.1016/j.jacc.2014.04.064.

139

Petrie MC, Jhund PS, She L, et al., STICH Trial Investigators. Ten-year outcomes after coronary artery bypass grafting according to age in patients with heart failure and left ventricular systolic dysfunction: An analysis of the extended follow-up of the STICH trial (Surgical Treatment for Ischemic Heart Failure). Circulation. 2016;134:1314-24. doi:10.1161/CIRCULATIONAHA.116.024800.

140

Shaw LJ, Berman DS, Maron DJ, et al; COURAGE Investigators. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: Results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008;117(10):1283-91. doi:10.1161/CIRCULATIONAHA.107.743963.

141

Hachamovitch R, Hayes SW, Friedman JD, et al. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation. 2003;107:2900-7. doi:10.1161/01.CIR.0000072790.23090.41

142

Gada H, Kirtane AJ, Kereiakes DJ, et al. Meta-analysis of trials on mortality after percutaneous coronary intervention compared with medical therapy in patients with stable coronary heart disease and objective evidence of myocardial ischemia. Am J Cardiol. 2015;115:1194-9. doi: 10.1016/j.amjcard.2015.01.556.

143

Stergiopoulos K, Boden WE, Hartigan P, et al. Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: A collaborative meta-analysis of contemporary randomized clinical trials. JAMA Intern Med. 2014;174:232-40. doi:10.1001/jamainternmed.2013.12855.

144

Nishigaki K, Yamazaki T, Kitabatake A, et al.; Japanese Stable Angina Pectoris Study Investigators. Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease a randomized, comparative, multicenter study. JACC Cardiovasc Interv. 2008;1:469-79. doi:10.1016/j.jcin.2008.08.002.

145

Al-Lamee R, Thompson D, Dehbi HM, et al., ORBITA Investigators. Percutaneous coronary intervention in stable angina (ORBITA): A double-blind, randomised controlled trial. Lancet. 2018;391:31-40. doi:10.1016/S0140-6736(17)32714-9.

146

Katritsis DG, Ioannidis JP. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: A meta-analysis. Circulation. 2005;111:2906-12. doi:10.1161/CIRCULATIONAHA.104.521864.

147

Schomig A, Mehilli J, de Waha A, et al. A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease. J Am Coll Cardiol. 2008;52:894-904. doi:10.1016/j.jacc.2008.05.051.

148

Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, et al. Percutaneous coronary interventions for non-acute coronary artery disease: A quantitative 20-year synopsis and a network metaanalysis. Lancet. 2009;373:911-8. doi:10.1016/S0140-6736(09)60319-6.

149

Bangalore S, Pursnani S, Kumar S, Bagos PG. Percutaneous coronary intervention versus optimal medical therapy for prevention of spontaneous myocardial infarction in subjects with stable ischemic heart disease. Circulation. 2013;127:769-81. doi:10.1161/CIRCULATIONAHA.112.131961.

150

Pursnani S, Korley F, Gopaul R, et al. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: A systematic review and metaanalysis of randomized clinical trials. Circ Cardiovasc Interv. 2012;5:476-90. doi:10.1161/CIRCINTERVENTIONS.112.970954.

151

Thomas S, Gokhale R, Boden WE, Devereaux PJ. A meta-analysis of randomized controlled trials comparing percutaneous coronary intervention with medical therapy in stable angina pectoris. Can J Cardiol. 2013;29:472-82. doi:10.1016/j.cjca.2012.07.010.

152

DeBruyne B, Fearon WF, Pijls NH, et al; FAME-2 Trial Investigators. Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med. 2014;371:1208-17. doi:10.1056/NEJMoa1408758.

153

Mironov VM, Merkulov EV, Samko AN. Assessment of the fractional reserve of blood flow. Cardiology. 2012;52(8):66-71. (In Russ.) Миронов В.М., Меркулов Е.В., Самко А.Н. Оценка фракционного резерва кровотока. Кардиология. 2012;52(8):66-71.

Mironov VM, Merkulov EV, Samko AN. Assessment of the fractional reserve of blood flow. Cardiology. 2012;52(8):66-71. (In Russ.)

154

Witberg G, Regev E, Chen S, et al. The prognostic effects of coronary disease severity and completeness of revascularization on mortality in patients undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2017;10:1428-35. doi:10.1016/j.jcin.2017.04.035.

155

Chakravarty T, Sharma R, Abramowitz Y, et al. Outcomes in patients with transcatheter aortic valve replacement and left main stenting: the TAVR-LM registry. J Am Coll Cardiol. 2016;67:951-60. doi:10.1016/j.jacc.2015.10.103.

156

Kaikita K, Ogawa H. Guidelines for Diagnosis and Treatment of Patients with Vasospastic Angina (Coronary Spastic Angina) (Revised Version 2013). Nihon Rinsho. 2016;74 Suppl 6:54-7.

157

Tanabe Y, Itoh E, Suzuki K, et al. Limited role of coronary angioplasty and stenting in coronary spastic angina with organic stenosis. J Am Coll Cardiol. 2002;39:1120-6. doi:10.1016/s0735-1097(02)01746-1.

158

Corcos T, David PR, Bourassa MG, et al. Percutaneous transluminal coronary angioplasty for the treatment of variant angina. J Am Coll Cardiol. 1985;5:1046-54. doi:10.1016/s0735-1097(85)80004-8.

159

Bertrand ME, LaBlanche JM, Thieuleux FA, et al. Comparative results of percutaneous transluminal coronary angioplasty in patients. J Am Coll Cardiol. 1986;8:504-8. doi:10.1016/s0735-1097(86)80174-7.

160

Prinzmetal M, Ekmekci A, Kennamer R, et al. Variantform of angina pectoris, previously undelineated syndrome. JAMA. 1960;174:1794-800. doi:10.1001/jama.1960.03030140016004.

161

MacAlpin RN. Relation of coronary arterial spasm to sites of organic stenosis. Am J Cardiol. 1980;46:143-53. doi:10.1016/0002-9149(80)90616-5.

162

Jeremias A, Kaul S, Rosengart TK, et al. The impact of revascularization on mortality in patients with nonacute coronary artery disease. Am J Med. 2009;122:152-61. doi:10.1016/j.amjmed.2008.07.027.

163

Aziz O, Rao C, Panesar SS, et al. Meta-analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery. BMJ. 2007;334(7594):617. doi:10.1136/bmj.39106.476215.BE.

164

Kapoor JR, Gienger AL, Ardehali R, et al. Isolated disease of the proximal left anterior descending artery comparing the effectiveness of percutaneous coronary interventions and coronary artery bypass surgery. JACC Cardiovasc Interv. 2008;1:483-91. doi:10.1016/j.jcin.2008.07.001.

165

Blazek S, Holzhey D, Jungert C, et al. Comparison of bare-metal stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: 10-year follow-up of a randomized trial. JACC Cardiovasc Interv. 2013;6:20-6. doi:10.1016/j.jcin.2012.09.008.

166

Hannan EL, Zhong Y, Walford G, et al. Coronary artery bypass graft surgery versus drugeluting stents for patients with isolated proximal left anterior descending disease. J Am Coll Cardiol. 2014;64:2717-26. doi:10.1016/j.jacc.2014.09.074.

167

Blazek S, Rossbach C, Borger MA, et al. Comparison of sirolimus-eluting stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: 7-year follow-up of a randomized trial. JACC Cardiovasc Interv. 2015;8:30-8. doi:10.1016/j.jcin.2014.08.006

168

Thiele H, Neumann-Schniedewind P, Jacobs S, et al. Randomized comparison of minimally invasive direct coronary artery bypass surgery versus sirolimus-eluting stenting in isolated proximal left anterior descending coronary artery stenosis. J Am Coll Cardiol. 2009;53:2324-31. doi:10.1016/j.jacc.2009.03.032.

169

Capodanno D, Stone GW, Morice MC, et al. Percutaneous coronary intervention versus coronary artery bypass graft surgery in left main coronary artery disease: A metaanalysis of randomized clinical data. J Am Coll Cardiol. 2011;58:1426-32. doi:10.1016/j.jacc.2011.07.005.

170

Giacoppo D, Colleran R, Cassese S, et al. Percutaneous coronary intervention vs coronary artery bypass grafting in patients with left main coronary artery stenosis: A systematic review and meta-analysis. JAMA Cardiol. 2017;2:1079-88. doi:10.1001/jamacardio.2017.2895.

171

Serruys PW, Morice MC, Kappetein AP, et al; SYNTAX Investigators S. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961-72. doi:10.1056/NEJMoa0804626

172

Park SJ, Ahn JM, Kim YH, et al; BEST Trial Investigators. Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med. 2015;372:1204-12. doi:10.1056/NEJMoa1415447

173

Chang M, Ahn JM, Lee CW, et al. Long-term mortality after coronary revascularization in nondiabetic patients with multivessel disease. J Am Coll Cardiol 2016;68:29-36. doi:10.1016/j.jacc.2016.04.034.

174

Head SJ, Davierwala PM, Serruys PW, et al. Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: Final five-year follow-up of the SYNTAX trial. Eur Heart J. 2014;35:2821-30. doi:10.1093/eurheartj/ehu213.

175

Hakeem A, Garg N, Bhatti S, et al. Effectiveness of percutaneous coronary intervention with drug-eluting stents compared with bypass surgery in diabetics with multivessel coronary disease: Comprehensive systematic review and meta-analysis of randomized clinical data. J Am Heart Assoc. 2013;2:e000354. doi:10.1161/JAHA.113.000354.

176

Herbison P, Wong CK. Has the difference in mortality between percutaneous coronary intervention and coronary artery bypass grafting in people with heart disease and diabetes changed over the years? A systematic review and meta-regression. BMJ Open. 2015;5:e010055. doi:10.1136/bmjopen-2015-010055.

177

Kamalesh M, Sharp TG, Tang XC, et al; CARDS Investigators VA. Percutaneous coronary intervention versus coronary bypass surgery in United States veterans with diabetes. J Am Coll Cardiol. 2013;61:808-16. doi:10.1016/j.jacc.2012.11.044.

178

Kappetein AP, Head SJ, Morice MC, et al, Investigators S. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg. 2013;43:1006-13. doi:10.1093/ejcts/ezt017.

179

Kapur A, Hall RJ, Malik IS, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol. 2010;55:432-40. doi:10.1016/j.jacc.2009.10.014.

180

Koskinas KC, Siontis GC, Piccolo R, et al. Impact of diabetic status on outcomes after revascularization with drug-eluting stents in relation to coronary artery disease complexity: Patient-level pooled analysis of 6081 patients. Circ Cardiovasc Interv. 2016;9:e003255. doi:10.1161/CIRCINTERVENTIONS.115.003255.

181

Windecker S, Stortecky S, Stefanini GG, et al. Revascularisation versus medical treatment in patients with stable coronary artery disease: Network meta-analysis. BMJ. 2014;348:g3859. doi:10.1136/bmj.g3859.

182

B0naa KH, Mannsverk J, Wiseth R, et al. Drug-eluting or bare-metal stents for coronary artery disease. N Engl J Med. 2016;375:1242-52. doi:10.1056/NEJMoa1607991.

183

Palmerini T, Benedetto U, Biondi-Zoccai G, et al. Long-term safety of drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2015;65:2496-507. doi:10.1016/j.jacc.2015.04.017.

184

Stefanini GG, Byrne RA, Windecker S. State of the art: coronary artery stent — past, present and future. EuroIntervention. 2017;13(6):706-16. doi:10.4244/EIJ-D-17-00557.

185

Sabate M, Windecker S, Iniguez A, et al. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: Results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur Heart J. 2016;37:229-40. doi:10.1093/eurheartj/ehv500.

186

Cassese S, Byrne RA, Ndrepepa G, et al. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: A meta-analysis of randomized controlled trials. Lancet. 2016;387:537-44. doi:10.1016/S0140-6736(15)00979-4.

187

Cassese S, Byrne RA, Juni P, et al. Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: A meta-analysis of randomized trials. EuroIntervention. 2018;13:1565-73. doi:10.4244/EIJ-D-17-00492.

188

Valgimigli M, Gagnor A, Calabro P, et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: A randomized multicentre trial. Lancet. 2015;385:2465-76. doi:10.1016/S0140-6736(15)60292-6.

189

Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): A randomized, parallel group, multicentre trial. Lancet. 2011;377:1409-20. doi:10.1016/S0140-6736(11)60404-2.

190

Ferrante G, Rao SV, Juni P, et al. Radial versus femoral access for coronary interventions across the entire spectrum of patients with coronary artery disease: A meta-analysis of randomized trials. JACC Cardiovasc Interv. 2016;9:1419-34. doi:10.1016/j.jcin.2016.04.014.

191

Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87-165. doi:10.1093/eurheartj/ehy394.

192

Gaudino M, Angelini G D, Antoniades C, et al. Off-Pump Coronary Artery Bypass Grafting: 30 Years of Debate. J Am Heart Assoc. 2018;7(16):e009934. doi:10.1161/JAHA.118.009934.

193

Melby SJ, Saint LL, Balsara K, et al. Complete coronary revascularization improves survival in octogenarians. Ann Thorac Surg. 2016;102:505-11. doi:10.1016/j.athoracsur.2016.01.065.

194

Taggart DP, Altman DG, Gray AM et al. Randomiz,ed trial of bilateral versus single internal-thoracic-artery grafts. N Engl J Med. 2016;375:2540-9. doi:10.1056/NEJMoa1610021.

195

Gaudino M, Tranbaugh R, Fremes S. Bilateral versus single internal thoracic artery grafts. N Engl J Med. 2017;376:e37. doi:10.1056/NEJMc1703358.

196

Gaudino M, Benedetto U, Fremes S, et al. Radial-artery or saphenous-vein grafts in coronary-artery bypass surgery. N Engl J Med. 2018; 378:2069-77. doi:10.1056/NEJMoa1716026.

197

Arora RR, Chou TM, Jain D, et al. Effects of enhanced external counter pulsation on Health-Related Quality of Life continue 12 months after treatment: a sub study of the Multicenter Study of Enhanced External Counter pulsation. J Investig Med. 2002;50:25-32. doi:10.2310/6650.2002.33514.

198

Zipes DP, Svorkdal N, Berman D, et al. Spinal cord stimulation therapy for patients with refractory angina who are not candidates for revascularization. Neuromodulation. 2012;15:550-8. doi:10.1111/j.1525-1403.2012.00452.x.

199

Henry TD, Losordo DW, Traverse JH, et al. Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials. Eur Heart J. 2018;39:2208-2216. doi:10.1093/eurheartj/ehx764.

200

Briones E, Lacalle JR, Marin-Leon I, Rueda JR. Transmyocardial laser revascularization versus medical therapy for refractory angina. Cochrane Database Syst Rev. 2015;2:CD003712. doi:10.1002/14651858.CD003712.pub3.

201

Dalal HM, Doherty P, Taylor RS. Cardiac rehabilitation. BMJ. 2015;351:h5000 doi:10.1136/bmj.h5000.

202

Taylor RS, Brown A, Ibrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med. 2004;116:682-92. doi:10.1016/j.amjmed.2004.01.009.

203

Clark AM, Hurtling L, Vandermeer B, McAlister FA. Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern Med. 2005;143:659-72. doi:10.7326/0003-4819-143-9-200511010-00010.

204

Постановление Правительства РФ от 16.05.2019 N 607 “О внесении изменений в Правила признания лица инвалидом”.

Decreet of the Government of the Russian Federation dated 16.05.2019 N 607 “On Amending the Rules for Recognizing a Person as Disabled.” (In Russ.)

205

Taylor RS, Unal B, Critchley JA, Capewell S. Mortality reductions in patients receiving exercise-based cardiac rehabilitation: how much can be attributed to cardiovascular risk factor improvements? Eur J Cardiovasc Prev Rehabil. 2006;13:369-74. doi:10.1097/01.hjr.0000199492.00967.11.

206

Chow CK, Jolly S, Rao-Melacini P, et al. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation. 2010;121:750-8. doi:10.1161/CIRCULATIONAHA.109.891523.

207

Aldcroft SA, Taylor NF, Blackstock FC, O'Halloran PD. Psychoeducational rehabilitation for health behavior change in coronary artery disease: a systematic review of controlled trials. J Cardiopulm Rehabil Prev. 2011;31:273-81. doi:10.1097/HCR.0b013e318220a7c9.

208

Heran BS, Chen JM, Ebrahim S, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2011;1:CD001800. doi: 10.1002/14651858.CD001800.pub2.

209

Janssen V, De Gucht V, Dusseldorp E, Maes S. Lifestyle modification programmes for patients with coronary heart disease: a systematic review and metaanalysis of randomized controlled trials. Eur J Prev Cardiol. 2013;20:620-40. doi:10.1177/2047487312462824.

210

Booth JN, 3rd, Levitan EB, Brown TM, et al. Effect of sustaining lifestyle modifications (nonsmoking, weight reduction, physical activity, and Mediterranean diet) after healing of myocardial infarction, percutaneous intervention, or coronary bypass (from the Reasons for Geographic and Racial Differences in Stroke Study). Am J Cardiol. 2014;113:1933-40. doi:10.1016/j.amjcard.2014.03.033.

211

Burning RS, Sturek M. Benefits of exercise training on coronary blood flow in coronary artery disease patients. Prog Cardiovasc Dis. 2015;57:443-53. doi:10.1016/j.pcad.2014.10.006.

212

Anderson L, Oldridge N, Thompson DR, et al. Exercise-based cardiac rehabilitation for coronary heart disease: Cochrane systematic review and meta-analysis. J Am Coll Cardiol. 2016;67:1-12. doi:10.1016/j.jacc.2015.10.044.

213

Rauch B, Davos CH, Doherty P, et al. The prognostic effect of cardiac rehabilitation in the era of acute revascularization and statin therapy: A systematic review and meta-analysis of randomized and non-randomized studies — The Cardiac Rehabilitation Outcome Study (CROS). Eur J Prev Cardiol. 2016;23:1914-39. doi:10.1177/2047487316671181.

214

Benzer W, Rauch B, Schmid JP, et al. Exercise-based cardiac rehabilitation in twelve European countries results of the 4916 European cardiac rehabilitation registry. Int J Cardiol. 2017;228:58-67. doi:10.1016/j.ijcard.2016.11.059.

215

Stewart RAH, Held C, Hadziosmanovic N, et al. Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. J Am Coll Cardiol. 2017;70:1689-700. doi:10.1016/j.jacc.2017.08.017.

216

Cheng W, Zhang Z, Cheng W, et al. Associations of leisure-time physical activity with cardiovascular mortality: A systematic review and meta-analysis of 44 prospective cohort studies. Eur J Prev Cardiol. 2018;25:1864-72. doi:10.1177/2047487318795194.

217

Lahtinen M, Toukola T, Junttila MJ, et al. Effect of Changes in Physical Activity on Risk for Cardiac Death in Patients With Coronary Artery Disease. Am J Cardiol. 2018;12:143-8. doi:10.1016/j.amjcard.2017.10.002.

218

Voogdt-Pruis HR, Beusmans GH, Gorgels AP, et al. Effectiveness of nurse-delivered cardiovascular risk management in primary care: a randomized trial. Br J Gen Pract. 2010;60:40-6. doi:10.3399/bjgp10X482095.

219

Wood DA, Kotseva K, Connolly S, et al. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomized controlled trial. Lancet. 2008;371:1999-2012. doi:10.1016/S0140-6736(08)60868-5.

220

Slater DK, Hlatky MA, Mark DB, et al. Outcome in suspected acute myocardial infarction with normal or minimally abnormal admission electrocardiographic findings. Am J Cardiol. 1987;60(10):766-70. doi:10.1016/0002-9149(87)91020-4.

221

Lev EI, Battler A, Behar S, et al. Frequency, characteristics and outcome of patients hospitalized with acute coronary syndromes with undetermined electrocardiographic patterns. Am J Cardiol. 2003;91(2):224-7. doi:10.1016/s0002-9149(02)03111-9.

222

Rahimi K, Watzlawek S, Thiele H, et al. Incidence, time course, and predictors of early malignant ventricular arrhythmias after non-ST-segment elevation myocardial infarction in patients with early invasive treatment. Eur Heart J. 2006;27:1706-11. doi:10.1093/eurheartj/ehl100.

223

Piccini JP, White JA, Mehta RH, et al. Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes. Circulation. 2012;126:41-9. doi:10.1161/CIRCULATIONAHA.111.071860.

224

Takx RA, Blomberg BA, El Aidi H, et al. Diagnostic accuracy of stress myocardial perfusion imaging compared to invasive coronary angiography with fractional flow reserve meta-analysis. Circ Cardiovasc Imaging. 2015;8(1):e002666. doi:10.1161/CIRCIMAGING.114.002666.

225

Danad I, Szymonifka J, Twisk JWR, et al. Diagnostic performance of cardiac imaging methods to diagnose ischaemia-causing coronary artery disease when directly compared with fractional flow reserve as a reference standard: a meta-analysis. Eur Heart J. 2017;38(13):991-8. doi:10.1093/eurheartj/ehw095.

226

Abdelmoneim SS, Dhoble A, Bernier M, et al. Quantitative myocardial contrast echocardiography during pharmacological stress for diagnosis of coronary artery disease: a systematic review and meta-analysis of diagnostic accuracy studies. Eur J Echocardiogr. 2009;10(7):813-25. doi:10.1093/ejechocard/jep084.

227

Mowatt G, Brazzelli M, Gemmell H, et al. Systematic review of the prognostic effectiveness of SPECT myocardial perfusion scintigraphy in patients with suspected or known coronary artery disease and following myocardial infarction. Nucl Med Commun. 2005;26(3):217-29. doi:10.1097/00006231-200503000-00006.

The authors declare that there are no conflicts of interest present.